Express Pharma
Home  »  Latest Updates  »  Aurobindo Pharma forms JV with Tergene Biotech to develop PCV

Aurobindo Pharma forms JV with Tergene Biotech to develop PCV

14

To set up a vaccine manufacturing facility as it plans to launch its vaccine products commercially in 2018

Aurobindo Pharma plans to set up a facility which would reportedly manufacture 50 million dosages of vaccines per annum. The company intends to launch its vaccine products commercially in 2018.

It has also established a joint venture (JV) with Tergene Biotech, a vaccine development company in Hyderabad, for developing pneumococcal conjugate vaccine (PCV). Tergene is currently working on development of the PCV.

“Aurobindo will hold a majority stake in the JV (with Targene Biotech) and will fund the product development in a phased manner spanning over three years. Development work for a few more products has commenced towards building a sizeable vaccines portfolio. Toxicology studies have been completed. A cGMP pilot plant for clinical lot manufacture is ready and we are now working on clinical trial protocols. The plans are to create infrastructure for 50 million dosage per annum, with the first phase launch being targeted for 25 million doses. All these efforts are being synchronised to achieve commercial launch of Aurobindo’s branded products in 2018,” informed the company in its annual report.

The location of the manufacturing facility was not disclosed. Reportedly, a new block to manufacture oncology API is also being built and the facility is expected to be operational in 2017-18.

EP News BureauMumbai

Comments are closed.